Stem Cell Treatments for Epilepsy: New Hope
Welcome to our blog post on stem cell treatments for epilepsy. In this article, we will explore the latest research and breakthroughs in stem cell therapy for epilepsy, offering new hope to individuals living with this challenging condition. By leveraging the power of regenerative medicine, researchers are paving the way for innovative treatments that have […]
Neurona Therapeutics’ Progress in Phase I/II Clinical Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Ep
Neurona Therapeutics, a clinical-stage biotherapeutics company, recently announced the completion of enrollment for the first cohort in its ongoing Phase I/II clinical trial of NRTX-1001. This investigational allogeneic cell therapy is being developed to treat drug-resistant mesial temporal lobe epilepsy (MTLE). The first cohort consisted of five subjects who received a one-time dose of NRTX-1001, […]
Exciting Advancements in Epilepsy Treatment: Neurona Therapeutics’ Breakthrough Research
Neurona Therapeutics, a pioneering biotherapeutics company, has recently unveiled groundbreaking research in the realm of regenerative cell therapy for neurological disorders. Their latest publication highlights the potential of a unique cell therapy approach to treat focal epilepsy, a condition that has long challenged the medical community due to its resistance to conventional drugs. Key Findings […]
Groundbreaking Cell Therapy NRTX-1001 Promises Over 90% Seizure Reduction: A New Hope for Drug-Resistant Epilepsy Patients
Neurona Therapeutics, a clinical-stage biotherapeutics company, has presented new data from its ongoing Phase I/II clinical trial of a one-time dose of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy (MTLE). The data shows a promising reduction in seizure frequency in the first and second patients at one year and seven-months post-treatment, respectively. The […]
Revolutionary Cell Therapy Shows Promise: Over 90% Seizure Reduction in Drug-Resistant Epilepsy Patients
Neurona Therapeutics, a clinical-stage biotherapeutics company, is developing regenerative cell therapies for the treatment of neurological disorders. They recently presented updated clinical data from their ongoing Phase I/II trial of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy (MTLE) at the American Academy of Neurology 2023 Annual Meeting. The data showed a >90% reduction […]
Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data
SAN FRANCISCO, Nov. 21, 2022 (GLOBE NEWSWIRE) — Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced that Cory R. Nicholas, Ph.D., Neurona’s president and chief executive officer, was invited to present an overview of Neurona’s regenerative cell therapy technology, proprietary manufacturing process, cell delivery system, and preclinical […]